Commentary: Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells [PDF]
Frontiers in Immunology, 2018 Mariana Pereira Pinho +1 more
doaj +4 more sources
Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. [PDF]
J Exp Med, 2004 CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation ...
Zinser E +4 more
europepmc +6 more sources
CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential
Frontiers in Immunology, 2019 CD83 is a member of the immunoglobulin (Ig) superfamily and is expressed in membrane bound or soluble forms. Membrane CD83 (mCD83) can be detected on a variety of activated immune cells, although it is most highly and stably expressed by mature dendritic
Ziduo Li +13 more
doaj +3 more sources
The CD83 Molecule – An Important Immune Checkpoint
Frontiers in Immunology, 2020 The CD83 molecule has been identified to be expressed on numerous activated immune cells, including B and T lymphocytes, monocytes, dendritic cells, microglia, and neutrophils.
Linda Grosche +9 more
doaj +3 more sources
The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells
Immunobiology, 2004 CD83 is the best-known surface marker for mature dendritic cells (DC) and recently we could show that a soluble form of CD83 inhibits DC maturation. In addition, this soluble form inhibits DC-mediated T cell proliferation in vitro and in vivo. Furthermore, several viruses induce CD83 degradation or shedding in infected DC.
Nicole, Kotzor +3 more
openaire +4 more sources
A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts [PDF]
Transplant International, 2007 CD83 is a surface marker expressed on matured dendritic cells (DCs). It plays a pivotal role in the mediation of DC/T cell interaction and induction of T-cell activation. Previous studies have suggested that a soluble form of CD83 could suppress DC maturation and inhibit T-cell activation and, as a result, it can prevent paralysis associated with ...
Jun-Fa, Xu +9 more
openaire +4 more sources
Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation. [PDF]
Eur J ImmunolStaphylococcal enterotoxin A (SEA) alters monocyte differentiation and function, while preserving T cell stimulatory capacity. SEA‐primed macrophages downregulate antigen‐presenting markers yet drive heightened T‐cell proliferation and IFN‐γ secretion.
Arasa C +4 more
europepmc +2 more sources
Transplant Immunology, 2021 Allogeneic transplantation immune tolerance is currently a hot research issue and soluble CD83(sCD83) is a novel immunomodulator with great potential in inducing transplantation tolerance.To investigate the mechanism of the immune tolerance effect of sCD83 on rat liver transplantation.A rat liver transplantation model was established to study the ...
Liangxing, Xiong +5 more
openaire +4 more sources
Alpha-toxin-elicited CX3CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytes [PDF]
mBioStaphylococcus aureus is an important human pathogen causing severe invasive infections. Pathogenesis is attributed to a wide array of virulence factors, including several potent exotoxins such as the pore-forming α-toxin.
Srikanth Mairpady Shambat +20 more
doaj +2 more sources
Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]
HLAABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Schenk HCM +8 more
europepmc +2 more sources